Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Neoadjuvant TAR-200/Cetrelimab Combo Shows Activity in Muscle-Invasive Bladder Cancer

September 16th 2024

Neoadjuvant TAR-200 plus cetrelimab elicited responses and was safe in muscle-invasive bladder cancer.

Dr Friedlander on AEs Associated With Enfortumab Vedotin in Bladder Cancer

September 16th 2024

Terence W. Friedlander, MD, discusses adverse effects that are associated with standard enfortumab vedotin in bladder cancer.

Addition of Perioperative Durvalumab to Neoadjuvant Chemo Generates Survival Benefits in Cisplatin-Eligible MIBC

September 15th 2024

NIAGARA was the first phase 3 study to evaluate perioperative immunotherapy plus neoadjuvant chemotherapy in cisplatin-eligible muscle-invasive bladder cancer.

utDNA Could Provide Noninvasive Tool for MRD Detection Prior to Repeat TURBT in High-Risk NMIBC

September 13th 2024

Joshua Linscott, MD, PhD, discusses the use of urinary cell-free tumor DNA for MRD detection prior to repeat resection in high-risk NMIBC.

Dr Linscott on the Use of Urinary Cell-free Tumor DNA to Predict MRD in High-Risk NMIBC

September 10th 2024

Joshua Linscott, MD, PhD, discusses the use of utDNA to predict MRD prior to repeat TURBT in patients with high-risk non-muscle invasive bladder cancer.

Dr Friedlander on Updates in Frontline Bladder Cancer Management

September 9th 2024

Terence W. Friedlander, MD, discusses updates in the frontline management of bladder cancer.

Dr Bochner on the Need for Multimodal Approaches in MIBC

September 4th 2024

Bernard H. Bochner, MD, FACS discusses genomic complexity and heterogeneity in bladder cancer tumors.

Dr Li on Safety Data Derived From the CORE-001 Trial in BCG-Unresponsive NMIBC

August 30th 2024

Roger Li, MD, discusses safety data from the final analysis of the CORE-001 trial in BCG-unresponsive non–muscle-invasive bladder cancer.

Dr Li on Cretostimogene Grenadenorepvec Plus Pembrolizumab in BCG-Unresponsive NMIBC

August 29th 2024

Roger Li, MD, discusses the final analysis of the CORE-001 trial of cretostimogene grenadenorepvec plus pembrolizumab in BCG-unresponsive NMIBC with CIS.

Enfortumab Vedotin Plus Pembrolizumab Approved in Europe for Metastatic Urothelial Cancer

August 28th 2024

The European Commission granted marketing authorization to frontline enfortumab vedotin plus pembrolizumab for unresectable/metastatic urothelial cancer.

Dr Cigliola on Potential Implications of the SURE-01 and SURE-02 Trials in MIBC

August 27th 2024

Antonio Cigliola, MD, discusses potential clinical implications of data from the phase 2 SURE-01 and SURE-02 trials in MIBC.

Dr Linscott on the Need for Improved MRD Detection in High-Risk NMIBC

August 23rd 2024

Joshua Linscott, MD, PhD, discusses a study evaluating a utDNA assay for minimal residual disease detection in patients with high-risk NMIBC.

Erdafitinib Wins EU Approval for FGFR3+ Unresectable, Metastatic Urothelial Carcinoma

August 23rd 2024

Erdafitinib was approved by the European Commission for pretreated unresectable or metastatic urothelial carcinoma harboring FGFR3 alterations.

Dr Nawfal on the Rationale for Assessing Radiological Tumor Burden in mccRCC

August 23rd 2024

Rashad Nawfal, MD, discusses radiological tumor burden as an independent prognostic factor for survival in metastatic clear cell renal cell carcinoma.

Enfortumab Vedotin Plus Pembrolizumab Approved in Canada for Advanced Bladder Cancer

August 22nd 2024

Enfortumab vedotin plus pembrolizumab has been approved by Health Canada for use in unresectable locally advanced or metastatic urothelial cancer.

Dr Li on the Clinical Implications of a Post Hoc Analysis of KEYNOTE-057 in BCG-Unresponsive NMIBC

August 22nd 2024

Roger Li, MD, discusses the implications of a post hoc analysis of the KEYNOTE-057 trial in BCG-unresponsive, high-risk non–muscle-invasive bladder cancer.

Dr Semaan on Liquid Biopsy vs Tissue Biopsy for Detecting Sarcomatoid RCC

August 20th 2024

Karl Semaan, MD, MSc, discusses the clinical advantages of liquid biopsy over tissue biopsies in detecting sarcomatoid renal cell carcinoma.

Enfortumab Vedotin Approved in China for Locally Advanced/Metastatic Urothelial Cancer

August 20th 2024

China’s National Medical Products Administration has approved enfortumab vedotin for adult patients with locally advanced or metastatic urothelial cancer.

Dr McGregor on the Clinical Implications of the DAD-IO Trial in Urothelial Carcinoma

August 20th 2024

Bradley McGregor, MD, discusses the clinical implications of the DAD-IO trial in patients with metastatic urothelial carcinoma.

Dr Shah on Real-World Treatment and Outcomes in Metastatic RCC After IO/TKI Combos

August 16th 2024

Neil J. Shah, MBBS, discusses treatment patterns and clinical outcomes in metastatic renal cell carcinoma after an immuno-oncology/TKI combination.